Generic Substitution Effects on Firm Level Market Shares in the Finnish Beta Blocker Market 1997Q1-2007Q4


The firm level market structure of the Finnish beta blocker market in the period from 1997Q1 to 2007Q4 is analyzed with data analysis and with panel data regression methods. Four different market concentration measures are used. Although drug prices have decreased in response to the competition-enhancing generic substitution system which started on the 1st of March 2003, the firms’ observed market shares in the market have not decreased uniformly in the all market dimensions. At the drug substitution group level, policy change has led to more equal group share distributions both for the nominal sales shares and quantity sales shares compared to the pre-policy period. At the whole market level, nominal firm sales shares of the largest firms have increased during the policy era but quantity sales shares have declined. The results imply that the dominant firms’ nominal sale shares are augmented with firm-specific drug price setting power. The results challenge the European Union (EU) drug policy targeted to increase competition in the drug markets.


Share and Cite:

M. Linden, "Generic Substitution Effects on Firm Level Market Shares in the Finnish Beta Blocker Market 1997Q1-2007Q4," Modern Economy, Vol. 4 No. 12, 2013, pp. 852-863. doi: 10.4236/me.2013.412092.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] D. Dranove and M. A. Satterthwaite, “The Industrial Organization of Health Care Markets,” In: A. J. Culyer and J. P. Newhouse, Eds., Handbook of Health Economics, Vol. 1, Elsevier, New York, 2000, pp. 1094-1139.
[2] M. Gaynor, “What Do We Know About Competition and Quality in Health Care Markets,” NBER wp-12301, Cambridge, 2006.
[3] M. Kyle, “Strategic Responses to Parallel Imports,” The B. E. Journal of Economic Analysis & Policy, Vol. 11, No. 2, 2011.
[4] P. Barros and X. Martinez-Giralt, “Health Economics: An Industrial Organization Perspective,” Routledge, London, 2012.
[5] G. Perry, “The European Generic Pharmaceutical Market in Review: 2006 and Beyond,” Journal of Generic Medicines, Vol. 4, No. 1, 2006, pp. 4-14.
[6] D. Simoens and S. De Coster, “Sustaining Generic Medicines Markets in Europe,” Journal of Generic Medicines, Vol. 3, No. 4, 2006, pp. 257-268.
[7] R. Miraldo, “Reference Pricing and Firms’ Pricing Strategies,” Journal of Health Economics, Vol. 28, No. 1, 2009, pp. 176-197.
[8] J. Puig-Junoy, “The Impact of European Pharmaceutical Price Regulation on Generic Price Competition: A Review,” Pharmacoeconomics, Vol. 28, No. 8, 2010, pp. 649-663.
[9] I. Moreno-Torres, J. Puig-Junoy and J.-R. Borrell, “Generic Entry into the Regulated Spanish Pharmaceutical Market,” Review of Industrial Organization, Vol. 34, No. 4, 2009, pp. 373-388.
[10] R. Reiffen and M. R. Ward, “Generic Drug Industry Dynamics,” Review of Economics and Statistics, Vol. 87, No. 1, 2005, pp. 37-49.
[11] M. A. Hurwitz and R. E. Caves, “Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals,” Journal of Law and Economics, Vol. 31, No. 2, 1988, pp. 299-320.
[12] H. G. Grabowski and J. M. Vernon, “Longer Patents for Increased Generic Competition in the US,” Pharmacoeconomics, Vol. 10, No. 2, 1996, pp. 110-123.
[13] L. Magazzini, F. Pammolli and M. Riccabonu, “Dynamic Competition in Pharmaceuticals. Patent Expiry, Generic Penetration, and Industry Structure,” European Journal of Health Economics, Vol. 5, 2004, pp. 175-182.
[14] K. Podnar, B. Molj and U. Golob, “How Reference Pricing for Pharmaceuticals Can Increase Generic Share of Markets: The Slovenian Experience,” Journal of Public Policy & Marketing, Vol. 26, No. 1, 2007, pp. 89-101.
[15] D.R. King and P. Kanavos, “Encouraging the Use of Generic Medicines: Implications for Transition Economics,” Croatian Medical Journal, Vol. 43, 2002, pp. 462-469.
[16] T. Aronsson, M. A. Bergman and N. Rudholm, “The Impact of Generic Drug Competition on Brand Name Market Shares-Evidence from Micro Data,” Review of Industrial Organization, Vol. 19, No. 4, 2001, pp. 425-435.
[17] J. Puig-Junoy, “Price Regulation Systems in the Pharmaceutical Market,” In: J. Puig-Junoy, Ed., The Public Financing of Pharmaceuticals, EE Publishers, London, 2005.
[18] D. Bernheim and M. Whinston, “Multimarket Contact an Collusive Behaviour,” Rand Journal of Economics, Vol. 21, 1990, pp. 1-26.
[19] J. Mestre-Ferrandiz, “The Impact of Generic Goods in the Pharmaceutical Industry,” Health Economics, Vol. 8, No. 7, 1999, pp. 599-612.<599::AID-HEC479>3.0.CO;2-K
[20] A. Hollis, “How Do Brand’s ‘Own Generics’ Affect Pharmaceutical Prices,” Review of Industrial Organization, Vol. 27, No. 4, 2005, pp. 329-350.
[21] F. J. Coronado-Saleh, “Market Structure and Regulation in Pharma-ceutical Markets,” Ph.D. Thesis, Universitat Pompeu Fabra, 2010.
[22] M. Waterson, “Economic Theory of the Industry,” Cambridge University Press, Cambrdge, 1984.
[23] P. Clarke and S. W. Davies, “Market Structure and Price Cost Margins,” Economica, Vol. 49, No. 195, 1982, pp. 277-287.
[24] P. J. Lambert, “Advanced Mathematics for Economist. Static and Dynamic Optimization,” Blackwell, 1985.
[25] A. Melnik, O. Shy and R. Stenbacka, “Assessing Market Dominance,” Journal of Economic Behaviour & Organization, Vol. 68, No. 1, 2008, pp. 63-72.
[26] J. D. Angrist and J.-S. Pischke, “Mostly Harmless Econometrics. An Empiricist Companion,” Princeton University Press, 2009.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.